Compare Fox Corp Class B (FOX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs GSK plc — how do they compare? Fox Corp Class B trades at $55.32 (market cap $24.58B), while GSK plc trades at $50.35 (market cap $102.60B). The key difference: GSK plc is far larger — about 4.2× Fox Corp Class B's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| FOX | GSK | |
|---|---|---|
Market Cap | $24.58B | $102.60B |
Sector | Media | Health |
52-Week High | $67.76 | $61.18 |
52-Week Low | $44.39 | $38.22 |
Enterprise Value | $27.94B | $123.04B |
Dividend Yield | 1.05% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.33, down 1.23% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings beats and strong 2025 results, including $16.3B revenue and $2.26B net income, support a P/E of 14.41. Positive news includes Tubi's partnership with Gracenote for CTV advertising growth (PRNewswire, Aug 12, 2026).
The outlook is positive with robust ad momentum and digital expansion, though risks include cyclical advertising exposure and high RSI suggesting near-term pullback potential. Analyst consensus leans neutral with 42.86% buy ratings, indicating cautious optimism for long-term holders amid competitive media pressures.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
